A Mobile-Based ChulaCancer LINE Chatbot for Supportive Management of Chemotherapy Adverse Events in Early-Stage Breast and Colorectal Cancer: A Pilot Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20251220014

Enrollment

Registered

2025-12-20

Start date

2024-12-04

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early breast and colon cancer patients receiving adjuvant outpatient chemotherapy Breast Neoplasms Colorectal Neoplasms Chemotherapy, Adjuvant Drug-Related Side Effects and Adverse Reactions Mobile Applications Telemedicine Quality of Life Randomized Controlled Trial

Interventions

ChulaCancer LINE Chatbot is a mobile chatbot that provides proactive educational videos and interactive menus for self-management of chemotherapy side effects. The intervention aims to improve symptom

Experimental Behavioral,No Intervention No treatment

ChulaCancer LINE Chatbot ,Usual care

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adults aged eighteen years or older, 2. ECOG performance status zero to two, 3. Planned to receive adjuvant chemotherapy or neoadjuvant chemotherapy, 4. Diagnosed with early stage colorectal cancer stage one to three and scheduled to receive CAPEOX chemotherapy, or diagnosed with early stage breast cancer stage one to three and scheduled to receive AC or TC chemotherapy, 5. Patient or caregiver has access to a mobile device with the LINE application, 6. Provides written informed consent.

Exclusion criteria

Exclusion criteria: 1. Unable to communicate in the Thai language, 2. History of any other malignancy prior to enrollment, 3. Treatment plan does not include chemotherapy, or includes concurrent chemoradiation, 4. Chemotherapy already initiated before study screening, 5. Unable to comply with the study follow-up schedule, 6. Unable to complete study questionnaires.

Design outcomes

Primary

Measure	Time frame
Rate of additional hospital visits due to chemotherapy-related side effects Baseline to week 12 after the first chemotherapy cycle Recorded from hospital electronic medical records and questionnaire	—

Secondary

Measure	Time frame
Change in quality-of-life scores Baseline, week 6, and week 12 after the first chemotherapy cycle Thai version of the EORTC QLQ-C30 questionnaire	—

Countries

Thailand

Contacts

Public ContactThiti Susiriwatananont

King chulalongkorn memorial hospital

thiti.su@chula.ac.th0892306088

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026